Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia

Hydroxyurea (HU) is a crucial therapy for children with sickle cell anemia, but its off‐label use is a barrier to widespread acceptance. We found HU exposure is not significantly altered by liquid vs capsule formulation, and weight‐based dosing schemes provide consistent exposure. HU is recommended...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical pharmacology 2016-03, Vol.56 (3), p.298-306
Hauptverfasser:	Estepp, Jeremie H., Melloni, Chiara, Thornburg, Courtney D., Wiczling, Paweł, Rogers, Zora, Rothman, Jennifer A., Green, Nancy S., Liem, Robert, Brandow, Amanda M., Crary, Shelley E., Howard, Thomas H., Morris, Maurine H., Lewandowski, Andrew, Garg, Uttam, Jusko, William J., Neville, Kathleen A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Anemia, Sickle Cell - blood Antisickling Agents - blood Antisickling Agents - pharmacokinetics Bioavailability bioequivalent Capsules Child Child, Preschool Exposure Female Humans Hydroxyurea - blood Hydroxyurea - chemistry Hydroxyurea - pharmacokinetics hydroxyurea. children Male Pharmacokinetics Prospective Studies Sickle cell anemia Solutions Therapeutic Equivalency
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!